Bliss GVS Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 21, 2025, 6:04 am

Quick Insight

Bliss GVS Pharma Ltd, a pharmaceutical company, currently trades at a price of 171 with a market cap of 1,802 Cr. The stock is valued at a P/E ratio of 16.9, indicating a moderate valuation. Despite a respectable ROE of 8.36% and ROCE of 11.7%, the company's OPM stands at 20%, reflecting decent operational efficiency. With promoters holding 35.10% and significant institutional ownership (FIIs at 13.51% and DIIs at 6.55%), the stock enjoys stable backing. The company's healthy reserves of 1,040 Cr and low borrowings of ₹88 Cr suggest a strong financial position. However, with a P/BV of 1.22x and ICR at 25.95x, investors may find the stock slightly overvalued, warranting caution in further investment decisions.

Competitors of Bliss GVS Pharma Ltd

All Competitor Stocks of Bliss GVS Pharma Ltd

Quarterly Result

Last Updated: August 1, 2025, 11:10 pm

Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 207.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 207.00 Cr., marking an increase of 9.00 Cr..
• For Expenses, as of Jun 2025, the value is 166.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 177.00 Cr. (Mar 2025) to 166.00 Cr., marking a decrease of 11.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 20.00 Cr..
• For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Mar 2025) to 20.00%, marking an increase of 9.00%.
• For Other Income, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 23.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 63.00 Cr., marking an increase of 40.00 Cr..
• For Tax %, as of Jun 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 29.00% (Mar 2025) to 30.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 27.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 4.08. The value appears strong and on an upward trend. It has increased from 1.47 (Mar 2025) to 4.08, marking an increase of 2.61.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 7:04 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:28 pm

Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 957.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 83.00 Cr..
• For Borrowings, as of Mar 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 100.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 12.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 17.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 370.00 Cr. (Mar 2024) to 406.00 Cr., marking an increase of 36.00 Cr..
• For CWIP, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 13.00 Cr..
• For Investments, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
• For Other Assets, as of Mar 2025, the value is 870.00 Cr.. The value appears strong and on an upward trend. It has increased from 830.00 Cr. (Mar 2024) to 870.00 Cr., marking an increase of 40.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,301.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..

Notably, the Reserves (1,040.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 7.23. This value is within the healthy range. It has increased from 6.83 (Mar 23) to 7.23, marking an increase of 0.40.
• For Diluted EPS (Rs.), as of Mar 24, the value is 7.11. This value is within the healthy range. It has increased from 6.72 (Mar 23) to 7.11, marking an increase of 0.39.
• For Cash EPS (Rs.), as of Mar 24, the value is 10.31. This value is within the healthy range. It has increased from 9.16 (Mar 23) to 10.31, marking an increase of 1.15.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 95.80. It has increased from 88.08 (Mar 23) to 95.80, marking an increase of 7.72.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 95.80. It has increased from 88.08 (Mar 23) to 95.80, marking an increase of 7.72.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 73.57. It has increased from 72.16 (Mar 23) to 73.57, marking an increase of 1.41.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 17.13. This value is within the healthy range. It has increased from 12.97 (Mar 23) to 17.13, marking an increase of 4.16.
• For PBIT / Share (Rs.), as of Mar 24, the value is 14.61. This value is within the healthy range. It has increased from 11.18 (Mar 23) to 14.61, marking an increase of 3.43.
• For PBT / Share (Rs.), as of Mar 24, the value is 11.16. This value is within the healthy range. It has increased from 10.18 (Mar 23) to 11.16, marking an increase of 0.98.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 7.79. This value is within the healthy range. It has increased from 7.37 (Mar 23) to 7.79, marking an increase of 0.42.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 7.21. This value is within the healthy range. It has increased from 6.80 (Mar 23) to 7.21, marking an increase of 0.41.
• For PBDIT Margin (%), as of Mar 24, the value is 23.28. This value is within the healthy range. It has increased from 17.97 (Mar 23) to 23.28, marking an increase of 5.31.
• For PBIT Margin (%), as of Mar 24, the value is 19.86. This value is within the healthy range. It has increased from 15.49 (Mar 23) to 19.86, marking an increase of 4.37.
• For PBT Margin (%), as of Mar 24, the value is 15.17. This value is within the healthy range. It has increased from 14.11 (Mar 23) to 15.17, marking an increase of 1.06.
• For Net Profit Margin (%), as of Mar 24, the value is 10.59. This value exceeds the healthy maximum of 10. It has increased from 10.20 (Mar 23) to 10.59, marking an increase of 0.39.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.79. This value is within the healthy range. It has increased from 9.42 (Mar 23) to 9.79, marking an increase of 0.37.
• For Return on Networth / Equity (%), as of Mar 24, the value is 7.80. This value is below the healthy minimum of 15. It has decreased from 8.01 (Mar 23) to 7.80, marking a decrease of 0.21.
• For Return on Capital Employeed (%), as of Mar 24, the value is 14.51. This value is within the healthy range. It has increased from 12.08 (Mar 23) to 14.51, marking an increase of 2.43.
• For Return On Assets (%), as of Mar 24, the value is 6.21. This value is within the healthy range. It has increased from 6.12 (Mar 23) to 6.21, marking an increase of 0.09.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.09. This value is within the healthy range. It has decreased from 0.11 (Mar 23) to 0.09, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.64. It has increased from 0.53 (Mar 23) to 0.64, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 24, the value is 5.08. This value exceeds the healthy maximum of 3. It has increased from 3.61 (Mar 23) to 5.08, marking an increase of 1.47.
• For Quick Ratio (X), as of Mar 24, the value is 4.34. This value exceeds the healthy maximum of 2. It has increased from 3.08 (Mar 23) to 4.34, marking an increase of 1.26.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.06. This value is below the healthy minimum of 4. It has increased from 2.96 (Mar 23) to 3.06, marking an increase of 0.10.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 6.90. This value is below the healthy minimum of 20. It has decreased from 7.32 (Mar 23) to 6.90, marking a decrease of 0.42.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.11. This value is below the healthy minimum of 20. It has decreased from 5.79 (Mar 23) to 5.11, marking a decrease of 0.68.
• For Earning Retention Ratio (%), as of Mar 24, the value is 93.10. This value exceeds the healthy maximum of 70. It has increased from 92.68 (Mar 23) to 93.10, marking an increase of 0.42.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.89. This value exceeds the healthy maximum of 70. It has increased from 94.21 (Mar 23) to 94.89, marking an increase of 0.68.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 25.95. This value is within the healthy range. It has increased from 13.04 (Mar 23) to 25.95, marking an increase of 12.91.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 17.03. This value is within the healthy range. It has increased from 8.40 (Mar 23) to 17.03, marking an increase of 8.63.
• For Enterprise Value (Cr.), as of Mar 24, the value is 1,087.33. It has increased from 770.70 (Mar 23) to 1,087.33, marking an increase of 316.63.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 1.03 (Mar 23) to 1.41, marking an increase of 0.38.
• For EV / EBITDA (X), as of Mar 24, the value is 6.06. This value is within the healthy range. It has increased from 5.70 (Mar 23) to 6.06, marking an increase of 0.36.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.53. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.53, marking an increase of 0.55.
• For Retention Ratios (%), as of Mar 24, the value is 93.09. This value exceeds the healthy maximum of 70. It has increased from 92.67 (Mar 23) to 93.09, marking an increase of 0.42.
• For Price / BV (X), as of Mar 24, the value is 1.22. This value is within the healthy range. It has increased from 0.83 (Mar 23) to 1.22, marking an increase of 0.39.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.53. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.53, marking an increase of 0.55.
• For EarningsYield, as of Mar 24, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.06, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness